Bafna Pharmaceuticals Ltd

NSE: BAFNAPH BSE: 532989

₹105.11

(-4.44%)

Sat, 14 Mar 2026, 00:31 am

MTF 5xInvest in Bafna Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap2.52B

PE Ratio25.74

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Bafna Pharmaceuticals EV/EBITDA Ratio

D/E EV EV/EBITDA P/B P/CF P/E P/S ROE %

Particulars	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Price to earnings ratio	0	0	0	24.33	24.42	20.91	45.29	17.87	22.67	8.97	0	0	0	0	0	55.74	57.59	17.24	24.68	42.73
Price to book ratio	0	0	0	0.68	1.48	1.41	1.36	1.06	0.46	0.77	0.97	1.29	1.75	1.36	0.04	5.72	4.85	2.66	2.24	2.09
Price to sales ratio	0	0	0	0.57	0.81	0.69	0.66	0.41	0.17	0.55	0.65	0.85	1.44	0.59	0.05	4.56	3.53	1.69	1.19	1.22
Price to cash flow ratio	0	0	0	0	0	0	0	2.84	0	0	0	0	0	0	0	0	31.12	59.34	24.85	9.08
Enterprise value	0	0	0	443.33M	884.42M	1.09B	1.67B	1.53B	1.39B	1.22B	1.34B	1.34B	1.08B	692.12M	-63.84M	3.36B	3.11B	2.11B	2.04B	2.02B
Enterprise value to EBITDA ratio	0	0	0	8.94	11.40	9.52	10.41	6.70	5.56	0	107.07	0	0	0	-4.97	32.52	25.96	13.39	18.01	17.69
Debt to equity ratio	2.02	0.92	1.92	0.53	0.73	0.94	1.34	1.50	1.59	0.96	1.39	1.93	1.23	2.43	0	0.23	0.18	0.31	0.30	0.33
Return on equity %	18.58	4.75	4.79	4.24	6.24	7.03	3.12	6.04	2.06	8.78	-21.66	-38.01	-41.53	-69.77	-5.37	10.80	8.79	16.63	9.52	5.01

Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio

The Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Bafna Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Bafna Pharmaceuticals Ltd (NSE: BAFNAPH, BSE: 532989) is currently trading at ₹105.11, with a market capitalization of ₹2.52B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.

Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Current Value

The current Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio stands at 17.69.

The Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Historical Trend

The Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:

2024: 17.69
2023: 18.01
2022: 13.39
2021: 25.96
2020: 32.52

The decline in Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.

What Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Indicates for Investors

The Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.

This ratio is an important metric used in fundamental analysis of Bafna Pharmaceuticals Ltd.

Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Analysis Summary

The Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Bafna Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800